Fasiglifam (TAK-875) is a small molecule agonist of the Free Fatty Acid Receptor 1 (FFAR1), which is also known as G-protein-coupled receptor 40 (GPR40) ([@kfx018-B31]), that was developed for the treatment of type 2 diabetes ([@kfx018-B4]; [@kfx018-B23]; [@kfx018-B30]). Clinical data indicated that there was a benefit for patients who received TAK-875 based on improved glycemic parameters ([@kfx018-B15]). However, the development activities of TAK-875 were voluntarily terminated in 2013 due to liver safety concerns ([@kfx018-B16], [@kfx018-B17]). This outcome presented an opportunity to investigate potential mechanisms of the toxicity with animal models. The hypothesis tested in the nonclinical studies was that TAK-875 alters bile acid (BA) homeostasis, which may be a contributing factor to drug induced liver injury (DILI).

Bile is comprised of a combination of bile acids (BAs), phospholipids (such as phosphatidylcholine), protein, cholesterol, fatty acid, and conjugated bilirubin ([@kfx018-B10]; [@kfx018-B32]). BAs are synthesized from cholesterol in the liver through a series of enzymatic steps ([@kfx018-B37]). The primary bile acids in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA) ([@kfx018-B47]). These 2 BAs undergo extensive modification that includes conjugation (with either taurine or glycine), reduction, dehydrogenation, oxidation, and cleavage to create a diverse BA pool ([@kfx018-B6]). In humans, most BAs in bile are conjugated to glycine ([@kfx018-B27]). BAs are exported from the liver into the bile and then secreted into the intestinal tract to aid in nutrient absorption ([@kfx018-B5]). As a part of enterohepatic circulation, BAs are reabsorbed in the ileum of the small intestine, enter the bloodstream, and return to the liver ([@kfx018-B13]). Some BAs are modified by bacterial enzymes in the intestine, which alters their rate of elimination or reabsorption ([@kfx018-B35]). In humans, this enterohepatic circulation loop runs 4--12 times a day and can recycle 95% of BAs ([@kfx018-B6]).

Movement into and out of hepatocytes is largely mediated by specific transport proteins because most BAs cannot undergo passive diffusion due to their ionic charges ([@kfx018-B8]). Detailed mechanisms of BA transport are extensively reviewed elsewhere ([@kfx018-B2]; [@kfx018-B6]; [@kfx018-B36]). Briefly, BA uptake into hepatocytes is mediated by Na^+^ taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs), while export is mediated by the bile salt export pump (BSEP) and multidrug resistance-associated proteins (MRPs) ([@kfx018-B12]). Both BSEP and MRP2 export BAs to the bile canaliculus while MRP3 and MRP4 transport to the blood ([@kfx018-B28]; [@kfx018-B46]). Unconjugated BAs can act as detergents that can cause liver injury if their concentration gets too high ([@kfx018-B27]). One protective mechanim is to conjugate the BAs to glycine or taurine in the liver as a means to promote canalicular transport ([@kfx018-B3]). There are other transporters, such as apical sodium-dependent bile salt transporter (ASBT) and organic solute transporter (OST)α/β, that also have a role in hepatic bile acid transport ([@kfx018-B46]).

Mutations of the human BSEP gene can lead to progressive hepatic cholestasis ([@kfx018-B33]; [@kfx018-B38]) and increase the susceptibility to drug-induced cholestasis ([@kfx018-B21]). BSEP knockout mice develop a mild form of cholestasis ([@kfx018-B44]) but other transporters are able to compensate and mitigate the severity of the disease ([@kfx018-B20]; [@kfx018-B43]). Chemicals that inhibit BSEP can cause cholestatic injury ([@kfx018-B9]). From a broader perspective, inhibition of BA transporter activity appears to be a contributing factor to DILI ([@kfx018-B1]; [@kfx018-B11]; [@kfx018-B19]). One recent model has established a link between the level of BSEP inhibition and the clinical exposure to predict whether the drug could cause DILI ([@kfx018-B29]).

Initial *in vitro* evidence that TAK-875 could inhibit multiple BA transporters prompted a more thorough mechanistic investigation. The results of this study describe nonclinical *in vitro* and *in vivo* findings about the effects of TAK-875 on BA homeostasis in animals. We hypothesized that TAK-875 inhibition of BA transporters may be a contributing factor to drug-induced liver effects in animals. Both TAK-875 and the primary glucuronide metabolite TAK-875-Glu were *in vitro* inhibitors of multiple BA transporters. Rats and dogs administered TAK-875 daily for 2 weeks had dose-dependent increases in the level of serum BAs. Additionally, the BA composition of dog bile was also significantly altered by TAK-875. This work demonstrates that TAK-875-mediated transporter inhibition alters BA homeostasis in animals, which in turn may be a contributing factor to DILI.

MATERIALS AND METHODS
=====================

Materials
---------

TAK-875 and TAK-875-Glu were synthesized internally at Takeda Pharmaceuticals.

Cell Based Assays
-----------------

Single donor cryopreserved human hepatocytes (lot HH1031) were obtained from In Vitro ADMET Laboratories (IVAL; Columbia, MD). Cells were thawed in UCRM media (IVAL) and plated in HQM media (IVAL) at 25,000 cells/well in collagen coated, clear-bottom 96-well plates and incubated overnight at 37 °C with 5% CO~2~. Four hours after plating, the media was replaced with HQM that contained 0.1% DMSO or test compounds dissolved in DMSO. Duplicate cell cultures were treated with 0.1--100 μM of TAK-875 or TAK-875-Glu. For cell viability assays, the CellTiter-Glo kit (Promega, Madison, WI, USA) was used to measure intracellular ATP after 6 or 24 h of incubation with the test compound. For glutathione quantification assays, the GSH-Glo kit (Promega) was used after 6 h of incubation. For both assays, luminescence was quantified using a Victor^3^ V Plate Reader (Perkin-Elmer, Waltham, MA). Data were analyzed in Prism 5 (Graphpad Software, La Jolla, CA), and the least-squares method was used to determine the concentration causing lethality for 50% of cells (LC~50~).

A Seahorse XFe96 Analyzer (Seahorse Bioscience, North Billerica, MA) was used to measure the mitochondrial effects of TAK-875 and TAK-875-Glu on hepatocytes. Cryopreserved primary human hepatocytes from a single donor were thawed and cultured on XF 96-well cell culture microplates (Seahorse Biosciences) in triplicate. The oxidative phosphorylation and glycolysis stress test media (Seahorse Biosciences) were prepared following manufacturer's instructions using protein-free media. Cells were maintained in a CO~2~-free incubator for 1 h at 37 °C prior to measuring the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 3 times over a 28 min span to establish a baseline. Compounds were added and the OCR and ECAR were measured in triplicate samples over a 42 min period. Data was analyzed with the XF Wave (v 2.3) software (Seahorse Bioscience). Results for the final measurement were normalized as a percentage of DMSO control wells.

For the glucose and galactose (Gluc-Gal) assay, HepG2 human hepatocellular carcinoma cells were plated on a 96-well cell culture microplate in DMEM (ThermoFisher Scientific, Cambridge, MA) supplemented with 10% fetal bovine serum (ThermoFisher Scientific) and cultured overnight. The next day, the medium was replaced with medium containing 25 mM glucose or 10 mM galactose. Cells were dosed in triplicate with either vehicle (0.5% DMSO) or a range of TAK-875 or TAK-875-Glu concentrations (in 0.5% DMSO) and incubated for 72 h at 37 °C. Cells were stained with Hoechst 33342 (Life Technologies, Carlsbad, CA) and viability was determined with an automated fluorescent cellular imager, ArrayScan VTI (ThermoFisher Scientific).

Transporter Assays
------------------

For transporters assay, membrane vesicles prepared from baculovirus-infected Sf9 insect cells that over expressed human transporters were purchased from GenoMembrane, Inc. (Yokohama, Japan). These included vesicles for BSEP (GM0005), MRP2 (GM0001), MRP3 (GM0021), and MRP4 (GM0012). HEK293 cells transfected with vectors containing OATP1B1 or OATP1B3 were obtained from ADME & Tox. Research Institute (Sekisui Medical Co., Tokyo, Japan). Radiolabeled substrates for the BSEP and NTCP assay (\[^3^H\]-taurocholate) and for the MRP2, MRP3, MRP4, OATP1B1, and OATP1B3 assays (\[^3^H\]Estradiol-17β-[d]{.smallcaps}-glucuronide) were purchased from PerkinElmer Life and Analytical Sciences (Waltham, Massachusetts). For the NTCP assay, the radiolabeled substrate (\[^3^H\]-taurocholate) was purchased from American Radiolabeled Chemicals (St. Louis, MO).

The BSEP and MRP2/3/4 assays were performed as described elsewhere ([@kfx018-B42]). Reaction incubation times were the following: BSEP, 1 min; MRP2, 2 min; MRP3, 15 min; MRP4, 15 min. Radioactivity was measured with a Tri-Carb 3100TR liquid scintillation counter (PerkinElmer) for the BSEP and MRP2 assays, and with a MicroBeta^2^ 2450 (PerkinElmer) for MRP3 and MRP4 assays. The OATP1B1 and OATP1B3 assays were performed as described elsewhere ([@kfx018-B34]). The reactions were terminated after 2 min, cells were washed in PBS, lysed with 0.1 M sodium hydroxide, and the radioactivity measured with a Hionic-Fluor scintillator (PerkinElmer). The NTCP assay was performed essentially as described ([@kfx018-B40]). Cryopreserved primary human hepatocytes were obtained from IVAL and were plated at 200,000 cells/well on a 48-well plate following manufacturer's instructions. Three hours after plating the cells were washed twice with Hanks\' Balanced Salts solution (HBSS) media (ThermoFisher Scientific) and incubated in HBSS media. Sodium-free buffer was used as a negative control. Uptake was initiated by adding HBSS containing 100 nM \[^3^H\]taurocholic acid in the absence or presence of multiple concentrations of TAK-875 or TAK-875-Glu. The assays were terminated after a 2 min incubation. The cells washed and lysed with 0.5% Triton X-100, and the radioactivity of cell lysates was assessed with a MicroBeta^2^ 2450 detector.

Rat Studies
-----------

Ten-week-old male Sprague Dawley rats were purchased from Charles River Laboratories (Charleston, SC) and acclimated to their surroundings for 5 days. The environmental conditions of the animal facility were: a 12:12 h light:dark cycle; a temperature of 18--29°C; a relative humidity of 50 ± 20%; and ventilation changes of ≥10 per hour. Animals were supplied with an autoclaved pellet diet (Lab Diet® \#5002, PMI Nutrition International LLC, St. Louis, MO) and *ad libitum* with reverse osmosis-filtered water. Twenty rats each received a 10 ml/kg oral gavage of vehicle (0.5% methylcellulose), 200 or 600 mg/kg TAK-875 for 14 consecutive days. Food was removed from the cage to fast animals the night before blood collection and returned at 6 h post-dose to minimize food effects. Whole blood was collected from 5 rats via the lateral tail vein in each dose group at predose, 1, 3, and 6 h on days 1, 7, and 14. Blood was collected from the vena cava from all animals 24 h after the final dose. To obtain serum, blood was collected into tubes containing no anticoagulant, allowed to clot, and centrifuged at 4 °C. Serum samples were analyzed with an AU680 Chemistry System (Beckman Coulter, Danvers, MA) by Idexx Laboratories (Grafton, MA). This system was used to measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), blood urea nitrogen (BUN), and total bile acids. For plasma, blood was collected into tubes containing ethylenediaminetetraacetic acid (EDTA) and centrifuged at 4 °C. Livers were collected at euthanasia fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4--6 μm, mounted on glass slides, stained with hematoxylin and eosin, and analyzed with an Olympus BX51 light microscope (Tokyo, Japan) for histopathology assessment by a board-certified veterinary pathologist. Euthanasia consisted of an intramuscular injection of an anesthetic cocktail (ketamine HCl \[75 mg/kg\], xylazine \[2.5 mg/kg\], and acepromazine \[2.5 mg/kg\]) and exsanguinations were performed in accordance with accepted American Veterinary Medical Association guidelines. One animal from both the vehicle-dosed (day 6) and from the 600 mg/kg TAK-875-dosed group (day 7) underwent unscheduled euthanasia due to moribund conditions that were not considered to be test article-related. All animal experiments for this study were conducted in accordance with Millennium Pharmaceutical's Institutional Animal Care and Use Committee Guidelines.

Dog Studies
-----------

Ten-month-old male Beagle dogs were purchased from Marshal BioResources (North Rose, NY, USA) and acclimated to their surroundings for 13 days. The environmental conditions of the animal facility were: a 12:12 h light:dark cycle; a temperature of 18--29°C; a relative humidity of 50 ± 20%; and ventilation changes of ≥10 per hour. Animals were supplied with PMI Nutrition International Certified Canine Chow (Lab Diet® \#5007, PMI Nutrition International LLC) and *ad libitum* with reverse osmosis-filtered water. The food ration was offered up to 2 h after dosing, and as an exception, animals were fed following the 6-h blood collection time point on Days 1, 7, and 14, and then fasted overnight prior to the 24-h time point. Six dogs each received a 5 ml/kg oral gavage of vehicle (0.5% methylcellulose), 40, 150, or 600 mg/kg TAK-875 for 14 consecutive days. Whole blood was collected from every animal at predose, 1, 3, 6, and 24 h after doses on days 1, 7, and 14 via venipuncture of the jugular vein. Whole blood was processed using the method described for rats. Serum samples were analyzed with an Olympus AU640e Chemistry Immuno Analyzer (Olympus) by Charles River Laboratories (Spencerville, OH). Bile was collected from the gall bladder at scheduled euthanasia. Liver samples were processed as described for rats. Euthanasia consisted of an injection with sodium pentobarbital followed by exsanguination. One dog that received 150 mg/kg TAK-875 underwent unscheduled euthanasia on day 8 for humane reasons due to a dose administration error. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals. All animal experiments for this study were conducted in accordance with Charles River Laboratories' Institutional Animal Care and Use Committee Guidelines.

Toxicokinetic Analysis
----------------------

The concentration of TAK-875 in the plasma samples was determined using a qualified liquid chromatography with tandem mass spectrometry (LC/MS/MS) method. A protein precipitation extraction method was used for sample preparation. Briefly, a Sciex API-4000 mass spectrometer (AB Sciex, Concord, Ontario, Canada) equipped with a Agilent 1200 LC System (Agilent Technologies, Santa Clara, CA) and a LEAP autosampler (LEAP Technologies, Carrboro, NC) used a reverse-phase gradient method running on an ACE C18 column (2.0 mm ID 2.0 × 50 mm; particle size 3 μm, \[Advanced Chromatography Technologies, Aberdeen, Scotland\]) for the analyte separation. The mobile phases used were in (A) 95:5 (v:v) water:acetonitrile and (B) 50:50 (v:v) methanol:acetonitrile, and both were supplemented with formic acid (0.1%, volume-to-volume ratio \[v:v\]). TAK-875 was ionized under a positive ion spray mode and detected through the multiple-reaction monitoring of a mass transition pair at a mass-to-charge ratio (*m/z*) of 525.6/465.2. Calibration curves of TAK-875 were established using standards, and the peak area ratios of the analyte against the internal standard (glyburide; Sigma-Aldrich, St. Louis, MO) were used to quantify samples. Toxicokinetic analysis of the individual plasma concentration data was performed using Phoenix WinNonlin, v.6.3 (Pharsight Corp, Mountain View, CA). Kinetic parameters were estimated using a noncompartmental model. The area under the curve during 24 h (AUC~0--24~) was calculated using the linear trapezoidal rule.

Individual Bile Acid Analysis
-----------------------------

The concentration of individual BAs in serum samples was determined by LC/MS/MS. Samples were prepared by extracting a 50 μl aliquot of serum with 200 μl acetonitrile containing 0.1% formic acid. The sources of the standards for the 21 different BAs are included in the [Supplementary Information](#sup1){ref-type="supplementary-material"}. BAs are either unconjugated, taurine (T)-conjugated, or glycine (G)-conjugated. The following BAs were measured: unconjugated BAs: UDCA, ursodeoxycholic acid; HDCA, hyodeoxycholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; CA, cholic acid; aMCA, alpha-muricholic acid; bMCA, beta-muricholic acid; LCA, lithocholic acid; T-conjugated BAs: TCA, taurodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; THDCA, taurohyodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; TLCA, taurolithocholic acid; TCA, taurocholic acid; TaMCA, tauro-alpha-muricholic acid; TbMCA, tauro-beta-muricholic acid; and G-conjugated BAs: GCA, glycocholic acid; GDCA, glycodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; GLCA, glycolithocholic acid.

For LC/MS/MS, an Eksigent MicroLC 200 system equipped with a QTRAP 5500 (AB Sciex) mass spectrometer and a LEAP autosampler running on a ACQUITY UPLC BEH C18 column (1.0 mm ID 2.1 × 50 mm; particle size 1.7 μm \[Waters Corporation, Milford, MA\]) at a flow rate of 50 µL/min for the analyte separation. The mobile phases used were (A) 25 mM ammonium acetate (pH 4) and (B) 10mM ammonium acetate in 90:10 (v:v) water:acetonitrile. The LC gradient used in this study is as follows (time \[minutes\], %B): 0, 32%; 1.6, 32%; 1.62, 38%; 6, 45%; 9, 45%; 13, 90%; 15.1, 90%. The gradient condition then returned to 32% B for equilibration. Internal standards using individual BAs were added before the precipitation. Calibration curves of BAs were established using standards for each analyte, and the peak area ratios of the analyte to internal standard were used to quantify samples.

Statistical Analyses
--------------------

Two different types of statistical analyses were utilized that depended on the type of data analyzed. First, comparisons were made between the means of treatment versus control groups with student *t*-tests (unpaired and 2-tailed). Second, the relationship between TAK-875 plasma concentrations and serum total BA concentrations in rats and dogs were assessed using Pearson\'s correlations. Statistical analyses were performed with GraphPad Prism (v6.07; GraphPad Software, La Jolla CA).

RESULTS
=======

The pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of TAK-875 were established in rats and dogs before the compound entered the clinic ([@kfx018-B31]). Glucuronidation to TAK-875-Glu ([Figure 1a](#kfx018-F1){ref-type="fig"}) is the primary elimination pathway of TAK-875 in rats, dogs and humans (manuscript in preparation). Therefore, both TAK-875 and TAK-875-Glu were characterized in cell-based assays to identify potential toxicities. Primary human hepatocytes were treated with a range of compound concentrations (0.1--100 µM) that bracketed the 4.4 µM maximal plasma concentration (*C*~max~) of a single 50-mg dose in humans ([@kfx018-B26]). Cells tolerated ≤25 µM of either compound at 6 and 24 h of treatment ([Figure 1b](#kfx018-F1){ref-type="fig"}). The mitochondrial effects of the compounds were assessed with a Seahorse XFe96 Analyzer. There were no effects on oxygen consumption or extracellular acidification at compound concentrations ≤20 µM ([Figure 1c](#kfx018-F1){ref-type="fig"}). Additionally, there was no evidence of glutathione depletion ([Figure 1d](#kfx018-F1){ref-type="fig"}) or production of reactive oxygen species ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}) that was indicative of reactive oxygen stress. Human HepG2 cells were then used to determine whether there were effects on glycolysis or mitochondrial oxidative phosphorylation by growing cells in media that contained either glucose (Gluc) or galactose (Gal) as an energy source ([@kfx018-B25]). The half maximal lethal concentration (LC~50~) was determined for cells treated with either TAK-875 or TAK-875-Glu ([Figure 1e](#kfx018-F1){ref-type="fig"}). The Gluc/Gal ratio was essentially the same between culture conditions, which was below the 2.0 threshold considered for a positive result ([@kfx018-B41]). FIG. 1TAK-875 and the primary metabolite TAK-875-Glu were evaluated in cell-based assays. A, The structures of TAK-875 and its primary metabolite TAK-875-Glu. B--D, Primary human hepatocytes were treated with the indicated concentrations of TAK-875 (box with solid line) or TAK-875-Glu (triangle with dashed line). Values are normalized to appropriate DMSO controls. B, Cells were treated with compounds for either 6 (left) or 24 (right) hours and survival was determined by intracellular ATP quantification. C, A Seahorse XFe96 Analyzer was used to assess mitochondrial effects of the indicated compounds on oxygen consumption (left) and extracellular acidification of the media (right). D, Levels of glutathione (GSH) after a 6 h incubation with compounds. E, Human HepG2 cells were incubated in media that contains glucose (Gluc) or galactose (Gal) as the only energy source. A nonlinear fit of the data was used to determine the LC~50~. Error bars indicate standard error of the mean.

The maintenance of BA homeostasis is a complicated process that involves numerous BA transport proteins ([@kfx018-B6]; [@kfx018-B36]). A schematic diagram of the principal influx (NTCP, OATPs) and efflux (BSEP, MRPs) transporters is shown in [Figure 2a](#kfx018-F2){ref-type="fig"}. Influx transporters include NTCP, OATP1B1 and OATP1B3, and efflux transporters include BSEP, MRP2, MRP3, and MRP4. The ability of TAK-875 and TAK-875-Glu to inhibit the human version of these transporters was evaluated *in vitro* and the corresponding half maximal inhibitory concentration (IC~50~) values were determined ([Figure 2b](#kfx018-F2){ref-type="fig"}). Both compounds inhibited human BSEP activity in a membrane vesicle assay ([Figure 2c](#kfx018-F2){ref-type="fig"}). Interestingly, TAK-875 stimulated then inhibited human MRP2 activity, while TAK-875-Glu was only inhibitory at the concentrations tested ([Figure 2d](#kfx018-F2){ref-type="fig"}). Taken together, both TAK-875 and TAK-875-Glu were inhibitors of multiple BA transporters at low micromolar concentrations. FIG. 2TAK-875 and TAK-875-Glu are *in vitro* inhibitors of BA transporters. A, Diagram of bile acid (BA) and conjugated BA (c-BA) influx and efflux into a hepatocyte. Once inside a hepatocyte, a BA can undergo conjugation with glycine or taurine. BAs and c-BAs are transported either to the bile duct canaliculus or back into the bloodstream. Figure modeled after [@kfx018-B28]. B, The IC~50~'s of TAK-875 and TAK-875-Glu against human BA transporters. Stim = a stimulatory effect was observed; N/A = assay was not performed. C, Human BSEP activity in the presence of TAK-875 (solid lines) or TAK-875-Glu (dashed lines). D, Human MRP2 activity. Error bars indicate standard error of the mean.

Animal studies were conducted to determine whether there was an actual *in vivo* relationship between the transporter assay data and effects on BAs *in vivo.* Rats received daily oral administration of 0, 200, or 600 mg/kg TAK-875 for 14 days. Fasted blood was collected on days 1, 7, and 14 for biomarker and TK analysis. The time of maximal plasma concentration (*T*~max~) for TAK-875 occurred at 6 h postdose for all groups and days ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). There were significant effects on total BA (TBA) levels within 3 h of TAK-875 dosing ([Figure 3a](#kfx018-F3){ref-type="fig"}). For the 600 mg/kg group, levels of TBA remained elevated throughout the 14 day study, even in samples collected 24 h after the previous dose. The serum levels of 2 biomarkers of liver injury, bilirubin ([Figure 3b](#kfx018-F3){ref-type="fig"}) and alanine aminotransferase (ALT) ([Figure 3c](#kfx018-F3){ref-type="fig"}), were elevated in the 600 mg/kg-dosed animals after the first week. However, other serum markers of liver damage remained at baseline ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}) and there was no correlative microscopic evidence of liver injury (data not shown). Additionally, there was no significant change in the amount of TBA in the feces of rats that received TAK-875 for 2 weeks ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}), or in the livers of rats that received 2 doses of TAK-875 ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Taken together, TAK-875 clearly affected the serum BA levels in rats but the ALT elevation was asymptomatic as there was no clear evidence of liver damage. The complete raw dataset for rats is presented in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. FIG. 3TAK-875 caused an increase in serum TBA and markers of liver damage in rats. Animals received a daily oral dose of 0, 200, or 600 mg/kg TAK-875 for 14 consecutive days. Serum from fasted rats was collected at predose (0 h) and 1, 3, and 6 h post-dose on days 1, 7, and 14. A, Group mean serum TBA levels. B, Serum bilirubin levels. C, Serum ALT levels. Error bars indicate standard error of the mean. An asterisk indicates a statistically significant (*P *\< .05) difference between treatment and control groups.

Dogs received daily oral administration of 0, 40, 150, and 600 mg/kg TAK-875 for 14 days. The TAK-875 *T*~max~ was approximately 1--3 h postdose ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Two of the 6 dogs at the 600 mg/kg level developed liver injury between day 7 and 14. The damage was characterized by granulomatous inflammation with neutrophils around an intralesional crystalline deposition ([Figure 4a](#kfx018-F4){ref-type="fig"}, white arrows). Biliary hyperplasia and fibroplasia were also present. Crystal formation within areas of granulomatous inflammation (black arrows) can be seen in both dogs "S" ([Figure 4b](#kfx018-F4){ref-type="fig"}) and "U" ([Figure 4c](#kfx018-F4){ref-type="fig"}). Similar crystal depositions collected from a previous dog study were identified by LC/MS as precipitated TAK-875 and its metabolite TAK-875-Glu (manuscript in preparation). No other dog had TAK-875-related microscopic changes. On day 14, the 2 dogs with liver injury had the highest serum levels of TBA, ALT, and bilirubin measured over the course of the study ([Figure 4d](#kfx018-F4){ref-type="fig"}). The mean serum TBAs are shown for groups 0, 40, 200, 600 (dogs T, V, W and X), and 600 mg/kg (dogs S and U) to illustrate the magnitude of changes ([Figure 4e](#kfx018-F4){ref-type="fig"}). Changes in other serum markers of liver damage are shown in ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}), and the complete data set is presented in [Supplementary Table 6](#sup1){ref-type="supplementary-material"}. FIG. 4TAK-875 caused liver injury in dogs. Animals received a daily oral dose of 0, 40, 150, or 600 mg/kg TAK-875 for 14 consecutive days. Livers were examined for microscopic damage, and black bars indicate 100 micrometers. A, Histology from dog "S" that received 600 mg/kg TAK-875. White arrows indicate granulomatous inflammation with neutrophils around intralesional crystalline. B, Dog "S" liver. Black arrows indicate areas of granulomatous inflammation. C, Liver from the 600 mg/kg dog "U" showing the injury. D, Serum from 24 fasted dogs (left, labeled "A" through "X") was collected predose (0 h) and at 0.5, 1, 3, 6, and 24 h post-dose on days 1, 7 and 14. Individual values (right) are shown for bilirubin (top), ALT (middle) and TBA (lower). (E) Group mean serum TBA for the 6 dogs that received 0, 40, and 150 mg/kg TAK-875. The 600 mg/kg group was further divided into those that did not have liver injury (dogs T, V, W, and X) and those that did (dogs S and U). Error bars indicate standard error of the mean.

The PK/PD relationship between the plasma concentration of TAK-875 and serum TBA was then assessed in both species. This analysis combined every time-matched plasma and serum sample across all dose groups. Measurements from vehicle-dosed animals were included to account for the natural variation of BA levels. A Pearson correlation coefficient analysis was conducted to determine the statistical significance (*P*) and the correlation coefficient (r) of the relationship. There was a strong correlation between TAK-875 concentrations and TBA levels for rats ([Figure 5a;](#kfx018-F5){ref-type="fig"}*r* = 0.77, *P* \< .0001) and dogs ([Figure 5b;](#kfx018-F5){ref-type="fig"}*r* = 0.51, *P* \< .0001). Thus, higher concentrations of TAK-875 are associated with increased levels of TBA in both animal species. FIG. 5Serum total bile acid levels are correlated to TAK-875 plasma concentration. For each sample, the TAK-875 plasma concentration was plotted against the time-matched serum TBA concentration. A linear regression line was generated by minimizing the sum of squares. The dotted line represents the 95% confidence band around the linear regression line. A Pearson\'s correlation coefficient analysis was conducted to determine the statistical significance (*P*) and the correlation coefficient (*r*) of the relationship. A, Rat; 234 plasma and serum samples that were collected across the entire study were analyzed. B, Dog; 426 plasma and serum samples.

Rat and dog serum samples were then analyzed by LC/MS/MS for 21 different BAs. This extensive data set is included as time-matched samples for both rats ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) and dogs ([Supplementary Table 6](#sup1){ref-type="supplementary-material"}). Analysis of the data revealed that the levels of many BAs changed in relation to the TAK-875 dose ([Supplementary Figs. 4--9](#sup1){ref-type="supplementary-material"}). At the end of the rat study, there was a significant 8-fold increase of CA in 600 mg/kg TAK-875 group versus control animals ([Figure 6a](#kfx018-F6){ref-type="fig"}). In dogs, there was a significant 250-fold increase in TCA in the two 600 mg/kg dogs with liver injury versus controls ([Figure 6b](#kfx018-F6){ref-type="fig"}), and a 7-fold increase versus the 600 mg/kg no-injury group. Bile was also collected from dogs and analyzed for individual BAs. Three BAs (TCA, TDCA and TCDCA) comprise 95% of BA in dog bile ([Figure 6c](#kfx018-F6){ref-type="fig"}). Interestingly, TAK-875 caused a significant increase in the proportion of TCA (upper line) in the bile that corresponded to a decrease in TDCA (lower line). The percentages of TCA and TDCA for the 2 dogs with liver injury, S and U, are labeled. By a Pearson correlation coefficient analysis, these dose-dependent trends were significant for both TCA (*P \< *.0028) and for TDCA (*P *\< .014). When these bile BA data are alternatively analyzed by dose, the 600 mg/kg group has 2.4-fold more TCA than TDCA ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}). Taken together, TAK-875 has clear BA effects on serum levels in rats and dogs, and in the bile of dogs. FIG. 6TAK-875 caused changes in the levels of individual BAs from rats and dogs. Serum or bile was collected from animals at the indicated time points and the levels of 21 individual bile acids were determined using LC/MS/MS. A--B, Bile acids are grouped by type of modification (unconjugated, taurine \[T\]-conjugated, or glycine \[G\]-conjugated). The doses and groups are displayed to the right of graphs. Asterisks indicate a statistically significant (*P *\< .05) difference in the means of treatment groups versus the control group. A, Rat serum was collected 24 h after the day 14 dose. B, Dog serum collected 6 h after the day 14 dose. The 600 mg/kg dose group was further divided into the 4 dogs without liver damage (no injury) and the 2 dogs with the liver damage (injury). C, Dog bile collected from animals 24 h after the day 14 dose. The proportion of each BA within the total BA pool was normalized for each animal. Plasma TK data was used to determine the day 14 exposure. The percentage of TCA, TDCA, and TCDCA are as shown; the remaining 18 BAs were combined into one value (All Others). A linear regression line was generated by minimizing the sum of squares. The dotted line shows a 95% confidence internal. A Pearson\'s correlation coefficient analysis was conducted to determine the statistical significance (*P*) and the correlation coefficient (*r*). Only statistically significant relationships (*P \< *.05) are shown. The TCA and TDCA data points for dogs "S" and "U" are labeled.

DISCUSSION
==========

The definitive cause for the liver effects seen in the TAK-875 clinical program remains unknown. Two of 6 dogs that received 600 mg/kg developed a liver injury that was characterized by crystalline deposition in the biliary duct with biliary hyperplasia and fibroplasia. In comparison, rats had an asymptomatic increase in serum ALT but no correlative microscopic evidence of liver damage. The key common finding between both species was a TAK-875 effect on the level of serum BAs.

Bile acid (BA) transporter inhibition can be identified by elevated serum BAs ([@kfx018-B36]). There was a clear relationship between TAK-875 plasma concentrations and serum TBA levels in both the rat ([Figure 5a](#kfx018-F5){ref-type="fig"}) and dog ([Figure 5b](#kfx018-F5){ref-type="fig"}). The first dose of 600 mg/kg TAK-875 caused a 5-fold increase of TBA in rats ([Figure 3a](#kfx018-F3){ref-type="fig"}) and an approximately 10-fold increase in dogs ([Figure 4e](#kfx018-F4){ref-type="fig"}) within a few hours of administration. TAK-875 and TAK-875-Glu inhibit multiple human BA transporters at similar low micromolar concentrations ([Figure 2a](#kfx018-F2){ref-type="fig"}). Similarly, TAK-875 was shown to be an inhibitor of multiple rat hepatobilliary transporters ([@kfx018-B24]). Taken together, the effects on serum TBA appear to be a direct result of BA transporter inhibition.

Repeated administration of 600 mg/kg TAK-875 caused crystalline depositions in the biliary tract of 2 dogs. The elevation of the serum markers of cholestasis, ALP and GGT, are consistent with this type of injury. Crystallization of TAK-875 and its primary metabolite TAK-875-Glu was also observed in 9-month repeat dose studies in dogs with 150 mg/kg TAK-875 (data not shown). Yet in rats, crystal formation was not observed in a 6-month rat study at doses up to 200 mg/kg (data not shown). In bile duct-cannulated studies, a single dose of 200 mg/kg TAK-875 did not impair bile flow in either rats or dogs (data not shown). Key biological and physiological differences between the species may explain the discrepancy. First, the rate of bile flow (normalized against body weights) is approximately 7-fold higher in rats than dogs ([@kfx018-B7]). Second, while rats and dogs predominantly have taurine-conjugated BAs, their respective BA pools have different compositions ([@kfx018-B39]; [@kfx018-B45]). And finally, rats naturally have very high levels of BSEP activity ([@kfx018-B14]) that may have made them less susceptible to TAK-875-mediated transporter inhibition. These and/or other potentially unknown factors may explain why the rat tolerated high doses of TAK-875 while dogs did not.

The mechanism behind the dramatic change in the bile BA composition of dogs administered TAK-875 is unknown. Both TCA and TDCA were at equal proportions in vehicle-dosed animals, but TAK-875 caused an increase in TCA with a corresponding decrease in TDCA ([Figure 6c](#kfx018-F6){ref-type="fig"}). Both TCA and TDCA are transported by BSEP, intestinal bacteria convert TCA to TDCA, and they are then reabsorbed in the gut as part of enterohepatic circulation ([@kfx018-B18]; [@kfx018-B22]). The 2 dogs with liver injury had 2.5-fold more TCA than TDCA, but so did other dogs without injury ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}), which suggests this is not the case of TCA accumulating at toxic levels. Unfortunately, bile was not analyzed for other parameters such as fatty acids, protein or bilirubin that could have provided insight into how the compound affected the bile. Future studies could also utilize bile duct cannulation to characterize the TAK-875 effects on bile using samples collected around the known plasma *C*~max~.

A recent model related to the plasma steady state concentration (*C*~ss~) of a drug and its inhibition of BSEP to liver injury has been reported ([@kfx018-B29]). This approach concluded that compounds with a low BSEP IC~50~ and a high *C*~ss~/BSEP IC~50~ ratio are at a higher risk for DILI ([@kfx018-B29]). The *C*~ss~ was 7.7 μM for a 50 mg dose of TAK-875 ([@kfx018-B23]), and the *in vitro* BSEP IC~50~ was 14.3 μM ([Figure 2b](#kfx018-F2){ref-type="fig"}). This C~ss~/BSEP IC~50~ ratio of 0.53 puts TAK-875 in the high risk zone using the Morgan *et al.* classification system. TAK-875 also stimulated MRP2 activity ([Figure 2d](#kfx018-F2){ref-type="fig"}). This is interesting given that multiple compounds that caused DILI were similarly found to be both BSEP inhibitors and MRP2 stimulators ([@kfx018-B29]). Screening of compounds for the inhibition/stimulation effects on BA transporters may be a useful first step in de-risking future programs.

Translating animal findings from nonclinical studies to human outcomes is extraordinarily difficult. One drawback of the TAK-875 hepatobilliary transporter hypothesis was much of the significant serum BA changes required doses of 600 mg/kg. For example, dogs had a TAK-875 plasma AUC~0--24~ of 3800 μg\*h/ml after 14 days of dosing at this concentration ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Humans were administered TAK-875 (fasiglifam) at 25 and 50 mg in phase 3 clinical trials that were ultimately discontinued due to concerns about liver safety ([@kfx018-B16], [@kfx018-B17]). By comparison of exposures, the 600 mg/kg dogs had an exposure approximately 40- to 100-fold greater than humans who received repeat doses of 25 or 50 mg TAK-875 (AUC~0--24~ of 40.3 and 100.3 μg\*h/ml, respectively) ([@kfx018-B23]). Unfortunately, there is no published information about BA levels in humans who received TAK-875. In conclusion, while TAK-875 BA transporter inhibition may have contributed to the liver injury of dogs, it is unclear whether these effects are relevant to humans at the clinical therapeutic doses.

SUPPLEMENTARY DATA
==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at *Toxicological Sciences* online.
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Click here for additional data file.
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